Home Business Thermo Fisher Scientific Acquires MTI-GlobalStem

Thermo Fisher Scientific Acquires MTI-GlobalStem


Thermo Fisher Scientific, the world leader in serving science, today announced it has signed a purchase agreement to acquire MTI-GlobalStem, a privately-held company that develops and commercializes leading-edge technology and reagents for cell transfection, neurobiology and stem cell research applications.

Completion of the transaction follows the receipt of all required regulatory approvals. Per the agreement, no further details of the transaction are being provided. Based in Gaithersburg, Md., MTI-GlobalStem will be folded into Thermo Fisher’s life sciences solutions segment.

“The addition of MTI-GlobalStem’s technology further strengthens Thermo Fisher’s leadership in biosciences and provides scientists around the world with access to a wider array of advanced research products designed to help accelerate discovery using cell models,” said Amy Butler, vice president and general manager of Cell Biology for Thermo Fisher Scientific.

“Their technology and expertise, combined with Thermo Fisher’s global commercial reach, is a strategic fit that enables us to better serve our transfection and stem cell research customers.”

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and more than 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

Previous articleHelix BioPharma Corp. announces the signing of a non-binding letter of intent with ProMab Biotechnologies to develop cell based therapies
Next articleFred Hutch announces $1M in grants to commercialize cutting-edge cancer and HIV research
CellTribune.com provides business and research news updates for the cell and gene therapy industry. CellTribune follows the companies and people who drive innovation in this exciting technology. The goal of CellTribune is to be recognized as the media leader and the go-to source for originally-reported, quality news coverage in this industry. We strive to become the link between budding companies, analysts and institutional investors. Submit your press release to Cell Tribune for immediate publication.